openPR Logo
Press release

Advanced Ovarian Cancer Pipeline, Clinical Trials, NDA Approvals, and Emerging Drugs 2023 | OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, and oth

07-05-2023 06:18 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Advanced Ovarian Cancer Pipeline, Clinical Trials, NDA

DelveInsight's, "Advanced Ovarian Cancer Pipeline Insight 2023" report provides comprehensive insights about 60+ companies and 70+ pipeline drugs in the Advanced Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Advanced Ovarian Cancer Pipeline Report
• DelveInsight's Advanced Ovarian Cancer Pipeline report depicts a robust space with 60+ active players working to develop 70+ pipeline therapies for Advanced Ovarian Cancer.
• The leading Advanced Ovarian Cancer Companies include OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Boehringer Ingelheim, Impact Therapeutics, Inc., Glycotope, Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc, and others.
• Promising Advanced Ovarian Cancer Pipeline Therapies include Bevacizumab, Durvalumab, Olaparib, Niraparib, ZL-2306 (Nirapairb), Fluzoparib, Paclitaxel, BIBF 1120, Karenitecin, Topotecan, and others.
• Advanced Ovarian Cancer companies and academics are working to assess challenges and seek opportunities that could influence Advanced Ovarian Cancer R&D. The Advanced Ovarian Cancer pipeline therapies under development are focused on novel approaches to treat/improve Advanced Ovarian Cancer.

Request a sample and discover the recent breakthroughs happening in the Advanced Ovarian Cancer Pipeline landscape @ Advanced Ovarian Cancer Pipeline Outlook- https://www.delveinsight.com/report-store/advanced-ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Advanced Ovarian Cancer Overview
Advanced Ovarian Cancer means that cancer has spread outside the ovaary. It may have spread within the pelvis or abdomen, or further away to other parts of the body such as the lungs. Some women have Advanced Ovarian Cancer when they are first diagnosed, and treatment can cure their cancer. This depends on several factors, including the exact stage of cancer.

Recent Developmental Activities in the Advanced Ovarian Cancer Treatment Landscape
• The US Food and Drug Administration (FDA) granted orphan drug designation to mirvetuximab to treat ovarian cancer; mirvetuximab has also secured this designation in the EU.
• In June 2018, the FDA granted mirvetuximab Fast Track designation to treat patients with a medium to high FRα-positive platinum-resistant ovarian cancer who got administered at least one but no more than three prior systemic treatment regimens for whom single-agent chemotherapy is apt as the following line of therapy.
• Stenoparib (2X-121), a unique, small molecule dual-targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2), was exclusively in-licensed by Allarity Therapeutics (globally) from Eisai and is currently being evaluated in Phase II clinical trial for advanced ovarian cancer.

For further information, refer to the detailed Advanced Ovarian Cancer Drugs Launch, Advanced Ovarian Cancer Developmental Activities, and Advanced Ovarian Cancer News, click here for Advanced Ovarian Cancer Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Advanced Ovarian Cancer Emerging Drugs Analysis
• Oregovomab: OncoQuest
• SC 10914: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
• Stenoparib: Allarity Therapeutics

Advanced Ovarian Cancer Pipeline Therapeutics Assessment
There are approx. 60+ key companies which are developing the therapies for advanced ovarian cancer. The companies which have their advanced ovarian cancer drug candidates in the most advanced stage, i.e. phase III include, OncoQuest.

Find out more about the Advanced Ovarian Cancer Pipeline Segmentation, Therapeutics Assessment, and Advanced Ovarian Cancer Emerging Drugs @ Advanced Ovarian Cancer Treatment Landscape- https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Advanced Ovarian Cancer Pipeline Report
• Coverage- Global
• Advanced Ovarian Cancer Companies- OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Boehringer Ingelheim, Impact Therapeutics, Inc., Glycotope, Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc, and others.
• Advanced Ovarian Cancer Pipeline Therapies- Bevacizumab, Durvalumab, Olaparib, Niraparib, ZL-2306 (Nirapairb), Fluzoparib, Paclitaxel, BIBF 1120, Karenitecin, Topotecan, and others.
• Advanced Ovarian Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Advanced Ovarian Cancer Pipeline Companies and Therapies, click here @ Advanced Ovarian Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Advanced ovarian cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Advanced ovarian cancer - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Advanced ovarian cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Oregovomab: OncoQuest
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. EP0057: Ellipses Pharma
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. DS-6000a: Daiichi Sankyo Company
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Advanced ovarian cancer Key Companies
23. Advanced ovarian cancer Key Products
24. Advanced ovarian cancer- Unmet Needs
25. Advanced ovarian cancer- Market Drivers and Barriers
26. Advanced ovarian cancer- Future Perspectives and Conclusion
27. Advanced ovarian cancer Analyst Views
28. Advanced ovarian cancer Key Companies
29. Appendix

Got Queries? Find out the related information on advanced ovarian cancer Mergers and acquisitions, advanced ovarian cancer Licensing Activities @ Advanced Ovarian Cancer Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Advanced Ovarian Cancer Pipeline, Clinical Trials, NDA Approvals, and Emerging Drugs 2023 | OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, and oth here

News-ID: 3113461 • Views:

More Releases from DelveInsight Business Research

Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of 13.30% by 2032, Evaluates DelveInsight
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR of 5.50% by 2032, Evaluates DelveInsight
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR of 6.65% by 2032, Evaluates DelveInsight
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of 6.86% by 2032, Evaluates DelveInsight
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts. DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides

All 5 Releases


More Releases for Advanced

Advanced Oxidation Technologies Market Size, Share 2021, Impressive Industry Gro …
The Advanced Oxidation Technologies Market is poised to take off in upcoming years hence showing a highly positive outlook through 2020-2028, according to a recently released report. Advanced Oxidation Technologies Market report covers industry chain analysis, latest market trends & dynamics along with cost profit analysis of major key players which focuses on expansion rate, prices, competition, size, prices, and value chain analysis of those leaders in the market. The
Medical Ceramics Market Analysis and Industry Forecast | Advanced Ceramics Resea …
Allied Market Research published a new report, titled, “Medical Ceramics Market by Type (Aluminum Oxide, Zirconia, and Carbon, Hydroxyapatite, Glass & Bioglass, Zirconia Alumina, Bioresorbable Ceramics, and Piezo Ceramics), by Application (Surgical Instruments, Diagnostic Equipment, Orthopedic Implants, Electronic Implants, Dental Implants, Disposables, and Packaging) – Global Opportunity Analysis and Industry Forecast, 2014 – 2022.” The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segment, Porter’s Five
Skincell Advanced Reviews – Does Skincell Advanced Really Work?
People want clear, blemish-free skin! However, most people have skin tags, moles, and warts. Some causes are known, while some blemishes are caused without any reason at all. When a regular skincare regimen fails, people turn to costly surgeries and medications. Cleansing and moisturizing might not work well for all. All skin types are not the same, and toners and skincare creams seldom give long-lasting benefits. Get Skincell Advanced From Its
Global Advanced Oxidation Technologies Market 2019- 2025 || A-Zone Technologies, …
Synopsis of the Advanced Oxidation Technologies Market: Latest Report on Advanced Oxidation Technologies Market deliberates the effect of various Factors influencing the market growth and drivers. Its further sheds light on market overview, key manufacturers, strategic adopted by them, size, latest trends and types, revenue, gross margin with regional analysis and forecast to 2025. Overview of the Advanced Oxidation Technologies Market Report: Advanced Oxidation Technologies Market report includes knowledge about the market overview
Global Advanced Materials Market - 3M Company, DowDuPont Inc, Hexcel Corporation …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market - By Product type (Structural Material, Functional Material, Emerging Material) By End User (Building & Construction, Automotive, Aerospace, Defense, Marine, Electrical & Electronics, Healthcare, Oil & Gas and Energy, Others) & Global Region - Market Size, Trends, Share and Forecast 2018-2023” research report will include all the major trends and technologies that
Global Advanced Materials Market: 3M Company, DowDuPont Inc, Hexcel Corporation, …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market 2017: Market Size, Trends & Opportunity Outlook – Forecast to 2023” research report will include all the major trends and technologies that play an important role in market growth in the predicted span of 6 years. It also presents the overview of industry players, advantages, challenges the business is going through. The